FDA approves Eli Lilly diabetes drug

Tirzepatide, a treatment for type 2 diabetes developed by Eli Lilly, has been approved by the FDA, setting the stage for a direct competition with Novo Nordisk’s Ozempic.


On Friday, US-based pharmaceutical firm Eli Lilly could announce that the US Food and Drug Administration (FDA) has approved tirzepatide for patients with type 2 diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs